Thoracic Surgery, University of Modena and Reggio Emilia, MODENA/IT, 2 Shanghai Pulmonary Hospital, Shanghai/CN Background: Thymectomy is recommended for the treatment of thymoma. The current literature suggests that minimally invasive surgery may be as effective or better than open thymectomy for treating small, early-stage thymic malignancies, possibly with no infiltration of the posterior structures. We show the potential benefits in an advanced thymoma undergoing thymectomy with subxiphoid approach. Method: A 55-year-old male came to our attention in May 2018 for blepharoptosis starting 3 months prior and worsening in the preceding month. Chest X-ray, CT scan, and RMI ( Fig. 1A-1B ) with enhancement showing a mass of 2 cm x 1.5 cm x 1 cm in the anterior mediastinum and infiltrating the joint position of the vena cava and the venae innominate and the anterior segment of the right upper lobe of the lung ( Fig.2A-2B ). The level of anti-acetylcholine antibodies in the blood was in the normal range, with no neurologic signs for myasthenia gravis. After clinical stabilization, the patient underwent thymectomy plus wedge resection of the right upper lobe of the lung using a subxiphoid approach. A hemostatic patch was used for pericardial repair. Results: Four hours operation with no intraoperative complications. Patient was extubated in the intensive care unit on the third postoperative day. Intravenous immunoglobulin was given immediately after surgery and pyridostigmine orally three days after surgery to prevent myasthenic crisis. Histology was positive for B3 thymoma Masaoka-Koga, stage IIIA. Patient was discharged after seven days,no morbidities and little pain. Conclusion: We believe think that the elevation of the sternum creates enough space through the anterior mediastinum to conduct more complicated procedures even if the thymoma is in an advanced stage, although a quality surgical experience, a highvolume surgical center, and careful selection of the patients are mandatory for improving postoperative outcomes. Fig.1A -B. RMI shows a thymoma infiltrating the vena cava and the right upper lobe of the lung. Fig.1C . Resection of the tumor at the joint position between the innominate vein and vena cava. Fig.1D . Thymus is completely removed. Keyword: thymoma, advanced stage, subxiphoid thymectomy, minimally invasive surgery. Background: In clinical practice, various treatments for advanced nonsmall-cell lung cancer (NSCLC) have been developed, aiming to alleviate the symptoms, prolong the survival and improve the life quality. Due to the absence of a standard multi-line treatment in advanced NSCLC, we hypothesized efficacy from rechallenge with pemetrexed alone or in combination with platinum or taxane for patients previously treated with pemetrexed. This article mainly observed the clinical efficacy and safety of rechallenge pemetrexed-based chemotherapy in locally advanced or metastatic NSCLC patients who had achieved first-line pemetrexed related benefitial response. Method: This retrospective study captured clinical data from 34 eligible pemetrexed rechallenge patients with advanced NSCLC who received benefitial response with first-line pemetrexedplatinum chemotherapy between January 2012 and December 2017.The progress time and safety of the disease were mainly observed. Results: With a median follow-up of 30.8 months, the DCR rate were 82.4%, with PR in 4 (11.8%) and SD in 24 (70.6%).Median rechallenge progression free survival(PFS) was 9.35 months, range from 0.9 to 44.2 months. Median overall survival (OS) was 42.2 months, range from 15.3 to 87.1 months. Patients with initial PFS (PFS1) of 10 months had a longer rechallenge PFS compared to those with a PFS1 of <10 months (median PFS: 9.23 vs. 3.40 months; P¼0.047).The significant prognostic factors for prolonging PFS after pemetrexed rechallenge are PFS1 (10 vs <10 months,HR,0.383;95% CI,0.153-0.960;P¼0.041) and line of rechallenge (2nd/3rd vs 4th, HR, 0.358; 95% CI, P¼0.025 (Lp(a) ) is considered to be one of the important risk factors for coronary heart disease (CHD) and calcific aortic valve stenosis (CAVS), In recent years, the concentration of Lp(a) has been found to be elevated in plasma in some cancer patients without cardiovascular disease, However, the involvement of Lp(a) in the development of oncology and its regulatory mechanism is not fully understood. Previous studies have suggested that QSOX (Quiescin/sulfhydryl oxidase) may be involved in the synthesis of Lp(a) in vitro, but whether the process has an abnormal activation in the tumour is unclear. Method: Serum samples from 75 patients with lung, stomach, colorectal and ovarian cancer without cardiovascular disease and 50 normal subjects were collected at random. Lp(a) concentration was measured by Immunoturbidimetric assay (ITA). The expression levels of QSOX1/2 in 32 patients with lung, gastric, colorectal and ovarian cancer were measured by Enzyme-
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